KMK Consulting’s Innovation and Customer Value Survey in breast cancer explores oncologists’ perspectives on the innovations they are looking forward to in the next two years, and the companies they see as best positioned to deliver them. To learn more view the infographic or click on the thumbnail below.

Oncologists cite the developments in targeted therapies like HER2+ and Parp inhibitors and the further development of immunotherapies as key innovations in breast cancer therapies over the next two years. To learn more about the study, view the press release, or contact us to discuss the survey results in detail: James Charnetski, james.charnetski@kmkconsultinginc.com; Gregory Chu, greg.chu@kmkconsultinginc.com